GENOME ANNOUNCEMENT {#s0}
===================

*Coxiella burnetii* is a Gram-negative intracellular bacterium that causes an influenza-like illness in humans called Q fever ([@B1]). Most infections occur through inhalation of aerosols originating from domestic livestock operations. Within the host cell, the pathogen becomes metabolically activated upon delivery into an acidic lysosome-like vacuole ([@B2]). The only *C. burnetii* virulence factor established in an immunocompetent animal model of infection is full-length lipopolysaccharide (LPS), which is synthesized by virulent phase I bacteria ([@B3]). Upon serial *in vitro* passage, phase I bacteria convert to avirulent phase II bacteria, which produce truncated LPS lacking O antigen and several core sugars ([@B4][@B5][@B8]).

The Nine Mile RSA439 (phase II, clone 4) strain (NMII) was derived from the Nine Mile strain, which was originally isolated in 1935 from the tick *Dermacentor andersoni* in Montana ([@B9]). The Nine Mile strain was passaged 94 times in embryonated hen's eggs and then plaque purified to generate NMII ([@B10], [@B11]). NMII has an \~26-kb chromosomal deletion that eliminates several LPS biosynthetic genes and is associated with the production of a severely truncated LPS ([@B12][@B13][@B16]). Because of clonality, avirulence in a guinea pig model of infection, and lack of phase reversion, NMII is considered a biosafety level 2 (BSL-2) bacterium ([@B3], [@B17], [@B18]). Other *C. burnetii* strains are considered BSL-3 bacteria and are regulated as select agents by the U.S. Centers for Disease Control and Prevention ([@B18]).

The NMII genome has not yet been sequenced; consequently, most researchers use the published genome of the Nine Mile RSA493 phase I strain (NMI) for reference ([@B19]). This occasionally leads to inconclusive results; for instance, the gene *caeA* is not annotated as a functional protein-coding gene in the NMI genome, but transcriptome analysis of NMII indicates its presence ([@B20], [@B21]). Thus, a fully annotated genome of the widely used NMII laboratory strain is needed to better understand the unique biology of this intracellular pathogen.

NMII was grown in ACCM-2 at 37°C in a 2.5% O~2~/5% CO~2~ environment in a tri-gas incubator (New Brunswick Scientific, NJ), as described previously ([@B22]). DNA was isolated from a 500-ml 7-day culture using phenol-chloroform with gentle cell disruption using a vortex adapter (Qiagen, CA) in order to minimize DNA fragmentation. DNA was sequenced using the PacBio RS II platform (Pacific Biosciences, USA), which generated a library containing 86,731 reads with an average length of 7,565 bp. Reads were assembled using HGAP 2.3.0 ([@B23]), which returned three contigs. The two chromosome contigs and the plasmid contig were closed in SSPACE 2.0 ([@B24]) using trimmed Illumina MiSeq 75-bp paired-end reads (5.50 million). Finally, CLC Genomics Workbench 6.5 (Qiagen) was used to map all Illumina and PacBio reads to the NMII chromosome (410× and 290× coverage, respectively) and plasmid (240× and 30× coverage, respectively) scaffolds to generate the consensus genome sequence. As expected, relative to the genome of NMI, homologs of genes CBU_0679 to CBU_0697 were completely deleted from the NMII genome ([@B3], [@B13][@B14][@B16]). In addition, partial deletions of homologs of CBU_0678, CBU_0698, and CBU_0918 and several single nucleotide polymorphisms were observed.
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The complete genome sequence of *C. burnetii* Nine Mile RSA439 (phase II, clone 4) has been deposited in GenBank under the accession numbers [CP020616](https://www.ncbi.nlm.nih.gov/nuccore/CP020616) (chromosome) and [CP020617](https://www.ncbi.nlm.nih.gov/nuccore/CP020617) (plasmid).
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